| All |
 |
Johnson & Johnson to Participate in Credit Suisse 18th Annual Health Care Conference
Nov 5, 2009
|
5.9 KB |
|
| |
NEW BRUNSWICK, N.J., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 18th Annual Health Care Conference on Thursday, Nov. 12, at the Arizona Biltmore Hotel. Dominic Caruso, Vice President, Finance and Chief Financial Officer, will present in a session scheduled at 1...
|
|
Johnson & Johnson Announces Restructuring Initiatives for Sustainable Growth
Nov 3, 2009
|
10.6 KB |
|
| |
NEW BRUNSWICK, N.J., Nov 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced global restructuring initiatives designed to strengthen the company's position as the world's leading global health care company. The company is taking steps to prioritize its innovation efforts around the many growth o...
|
|
Xerox Chairman Anne M. Mulcahy Appointed to Johnson & Johnson Board of Directors
Oct 22, 2009
|
6.0 KB |
|
| |
NEW BRUNSWICK, N.J., Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Anne M. Mulcahy, Chairman of Xerox Corporation (NYSE: XRX), today was appointed to the Board of Directors of Johnson & Johnson (NYSE: JNJ), the world's most broadly based health care products company.
Mulcahy was both chairman and chief executive officer of Xerox u...
|
|
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Oct 19, 2009
|
19.8 KB |
|
| |
PHILADELPHIA, Oct 19, 2009 /PRNewswire via COMTEX News Network/ -- New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These ne...
|
|
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Oct 19, 2009
|
22.8 KB |
|
| |
PHILADELPHIA, Oct 19, 2009 /PRNewswire via COMTEX News Network/ -- Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and ...
|
|
Biosense Webster Receives FDA Clearance for the CARTO(R) 3 System
Oct 15, 2009
|
16.8 KB |
|
| |
DIAMOND BAR, Calif., Oct 15, 2009 (BUSINESS WIRE) -- Biosense
Webster, Inc., a worldwide leader in the diagnosis and treatment of
cardiac arrhythmias, announced today that the U.S.
Food and Drug Administration (FDA) has cleared for marketing the
CARTO(R) 3 System, the most advanced three-dimensional imaging
t...
|
|
Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
Oct 14, 2009
|
11.7 KB |
|
| |
RARITAN, N.J. (Oct. 14, 2009) - Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS®...
|
|
Johnson & Johnson Reports 2009 Third-Quarter Results:
Oct 13, 2009
|
39.0 KB |
|
| |
NEW BRUNSWICK, N.J., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined ...
|
|
Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Medical Devices & Diagnostics Business
Oct 6, 2009
|
6.0 KB |
|
| |
NEW BRUNSWICK, N.J., Oct 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 13, 2009, to discuss third-quarter financial results and review its Medical Devices & Diagnostics business. The meeting will be hosted by Alex Gorsky, Worldwide Chairman, Me...
|
|
Simponi™ (Golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis With Novel Smartject™ Autoinjector
Oct 6, 2009
|
18.9 KB |
|
| |
HORSHAM, Pa. and KENILWORTH, N.J., October 6, 2009 - Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the European Commission has approved SIMPONI™ (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progr...
|
|
Cordis Corporation Announces Agreement with Boston Scientific to Settle Selected Stent Litigation Cases
Sep 29, 2009
|
9.7 KB |
|
| |
BRIDGEWATER, N.J., Sep 29, 2009 (BUSINESS WIRE) -- Cordis Corporation ("Cordis") announced today that it has reached an
agreement with Boston Scientific ("Boston") resolving its Palmaz
infringement suit relating to Boston's NIR stent, settling several other
cardiology-related cases relating to patents in the Ding, Kastenhofe...
|
|
Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment
Sep 28, 2009
|
15.0 KB |
|
| |
NEW BRUNSWICK, N.J., and LEIDEN, Netherlands, Sept 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) and Crucell, N.V., (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Crucell have entered into a strate...
|
|
STELARA ™ (ustekinumab) Receives FDA Approval For Treatment Of Moderate To Severe Plaque Psoriasis With Four-Times-A-Year Maintenance Dosing
Sep 25, 2009
|
15.3 KB |
|
| |
HORSHAM, Pa., September 25, 2009 -- Centocor Ortho Biotech Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA (ustekinumab) for the treatment of adult patients 18 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The efficacy and safety of STEL...
|
|
NEVO(TM) Sirolimus-Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months Than Taxus(R) Liberte(R) Stent
Sep 24, 2009
|
13.3 KB |
|
| |
SAN FRANCISCO, Sep 24, 2009 (BUSINESS WIRE) -- At six months, patients receiving the NEVO(TM) Sirolimus-eluting
Coronary Stent reported significantly less chest pain (also known as
angina) than those receiving the Taxus(R) Liberte(R)
Stent. Patients also reported improvements in their overall quality of
life. These d...
|
|
Janssen-Cilag's STELARA®▼ (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Sep 23, 2009
|
15.5 KB |
|
| |
HIGH WYCOMBE, England, September 23 /PRNewswire/ -- STELARA (ustekinumab) has today been approved by the National Institute for Health and Clinical Excellence (NICE) as a treatment option for adults with moderate to severe plaque psoriasis,(1) a notoriously difficult-to-treat kin condition for which many patients report feeling dissatisfied and ...
|
|
2.25 MM CYPHER(R) Sirolimus-eluting Coronary Stent Approved by FDA
Sep 21, 2009
|
14.4 KB |
|
| |
BRIDGEWATER, N.J., Sep 21, 2009 (BUSINESS WIRE) -- Cordis
Corporation, a worldwide leader in the development and manufacture
of interventional vascular technology, announced today that it has
received approval from the U.S. Food
and Drug Administration (FDA) for a new, smaller version of the CYPHER(R)
Sirolim...
|
|
Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equity Investment
Sep 17, 2009
|
10.7 KB |
|
| |
NEW BRUNSWICK, N.J., & DUBLIN, Sep 17, 2009 (BUSINESS WIRE) -- Johnson & Johnson (NYSE:JNJ) and Elan Corporation plc (NYSE:ELN) today
announced that JANSSEN Alzheimer Immunotherapy, a newly formed
subsidiary of Johnson & Johnson, has completed the acquisition of
substantially all of the assets and rights of Elan related to i...
|
|
Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding Doxil( R) for the Treatment of Advanced Breast Cancer
Sep 10, 2009
|
11.7 KB |
|
| |
Horsham, Pa., September 10, 2009 - Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women...
|
|
FDA Issues Complete Response Letter for Trabectedin Combined with DOXIL
Sep 10, 2009
|
6.5 KB |
|
| |
Horsham, Pa., September 10, 2009 — Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL® (doxorubicin HCI liposome injection) for the t...
|
|
Johnson & Johnson to Participate in Morgan Stanley Global Healthcare Unplugged Conference
Sep 8, 2009
|
5.7 KB |
|
| |
NEW BRUNSWICK, N.J., Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 15th, at the Grand Hyatt in New York. Alex Gorsky, Worldwide Chairman, Surgical Care for Johnson & Johnson, will represent the Company...
|
|
|
